A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- Sponsors Oshadi Drug Administration
- 16 Apr 2018 Status changed from recruiting to completed.
- 28 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017 as per ClinicalTrials.gov record.